DYAI
Dyadic International, Inc.
NASDAQ · Healthcare · Biotechnology · US
$0.52
+3.89%Aug 13, 2026, 12:00 UTC
Dyadic International, Inc. announced definitive agreements with an institutional investor for a registered direct offering of common stock and a concurrent private placement of warrants, raising approximately $2.9 million.
Source:Aug 12, 2026, 12:30 UTC
Dyadic International reported its financial results for the second quarter ended June 30, 2026, highlighting progress in product commercialization, strategic partnerships, and C1 biomanufacturing platform expansion.
Aug 4, 2026, 11:25 UTC
Dyadic International announced a new development and commercial license agreement with a European biotechnology company to expand its commercial non-animal dairy pipeline with additional precision-fermented dairy proteins.
Source:Jul 16, 2026, 12:00 UTC
Dyadic International announced the expansion of its bio-industrial pipeline with a new proprietary industrial enzyme program focused on advanced cellulose processing.
Source:Jun 29, 2026, 11:25 UTC
The Japan Patent Office allowed claims covering Dyadic International's proprietary Thermothelomyces heterothallica recombinant protein expression technology.
Source: